This study is a prospective, multicenter, open-label, randomized controlled clinical trial, planned to enroll 30 patients with advanced gastric cancer and peritoneal metastasis. It aims to evaluate the safety and efficacy of systemic therapy plus Pressurized Intra-Peritoneal Aerosol Virus (PIPAV) with VRT106 compared to systemic therapy plus Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of adverse events
Timeframe: From the screening period to 28 days after the last intraperitoneal perfusion treatment during the follow-up period
Incidence of serious adverse events
Timeframe: From the screening period to 28 days after the last intraperitoneal perfusion treatment during the follow-up period
Eastern Cooperative Oncology Group Performance status
Timeframe: From the screening period to 28 days after the last intraperitoneal perfusion treatment during the follow-up period
Surgical complications
Timeframe: From the screening period to 28 days after the last intraperitoneal perfusion treatment during the follow-up period
Postoperative pain score (Visual Analogue Scale/VAS score)
Timeframe: At the beginning of Cycle 1 (each cycle lasting 28 days), at the beginning of Cycle 2 (each cycle lasting 28 days), and at the beginning of Cycle 3 (each cycle lasting 28 days)